KDM4A and neoplasm: As more highly specific KDM4A inhibitors with favourable in vivo pharmacology have not yet come to fruition,30 we tested therefore the efficacy of PKF118–310 as it had been tested previously through intra-tumoral injections in vivo.31,32 We used a well-established MSTO xenograft tumour mouse model and injected PKF118–310 within its toxicity limits (Fig. 2b).